DaVita Inc. (NYSE:DVA) Shares Acquired by Sei Investments Co.

Sei Investments Co. lifted its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 212.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 90,769 shares of the company's stock after acquiring an additional 61,731 shares during the period. Sei Investments Co. owned 0.11% of DaVita worth $13,578,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Amundi increased its stake in DaVita by 116.4% in the 4th quarter. Amundi now owns 446,386 shares of the company's stock valued at $68,726,000 after buying an additional 240,126 shares during the period. FMR LLC boosted its position in shares of DaVita by 659.9% in the 3rd quarter. FMR LLC now owns 177,406 shares of the company's stock worth $29,082,000 after buying an additional 154,061 shares in the last quarter. Skandinaviska Enskilda Banken AB publ grew its position in shares of DaVita by 256.8% in the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 162,233 shares of the company's stock valued at $24,301,000 after purchasing an additional 116,758 shares during the last quarter. JPMorgan Chase & Co. increased its position in DaVita by 17.8% during the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company's stock worth $99,846,000 after buying an additional 92,014 shares in the last quarter. Finally, Strategic Financial Concepts LLC acquired a new position in DaVita in the 4th quarter valued at about $9,371,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Stock Up 1.6 %

NYSE DVA traded up $2.46 during mid-day trading on Wednesday, reaching $154.37. 710,606 shares of the company's stock traded hands, compared to its average volume of 808,481. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 1-year low of $125.64 and a 1-year high of $179.60. The company has a fifty day simple moving average of $156.49 and a 200-day simple moving average of $157.41. The company has a market cap of $12.35 billion, a price-to-earnings ratio of 14.37, a P/E/G ratio of 1.07 and a beta of 0.99.

Remove Ads

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. As a group, equities research analysts expect that DaVita Inc. will post 10.76 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on DVA shares. Cowen reiterated a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. StockNews.com lowered DaVita from a "buy" rating to a "hold" rating in a research note on Wednesday. Barclays boosted their price target on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a research report on Friday, February 21st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the stock. According to MarketBeat, DaVita presently has a consensus rating of "Hold" and an average price target of $166.33.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.